Table 1.

Clinicopathologic Features and E2EPF Expression Profile in PRCC Patients with Oncologic Follow-Up

Code	Institute	Method	Sex	Size	Subtype	T	N	MT	Grading	E2-EPF	HIF1α	Status	Survival
2883	MZ	TMA, WB	M	30	1	1	0	0	3	Low	Low	NED	83,0
2581	MZ	WB	F	53	1	1	0	0	2	Low	Low	NED	120,0
2873	MZ	TMA	M	80	1	3			2	Low	NA	NED	85,0
2900	MZ	TMA, WB	F	120	1	2	0		2	Low	Low	NED	78,0
2540	MZ	TMA	M	25	1	3			2	High	NA	NED	181,8
2559	MZ	TMA, WB	F	50	1	1			2	Low	Low	NED	120,0
2807	MZ	TMA, WB	M	60	1	1	0	0	1	Low	Low	DOD	34,0
2835	MZ	TMA	M	35	1	3	1	1	4	High	NA	DOD	5,0
76864	VA	TMA	M	35	1	1	0	0	2	Low	NA	NED	13,0
76886	VA	TMA	F	25	1	1	0	0	2	Low	NA	NED	4,0
2818	MZ	TMA, WB	F	105	2	2	0		2	Low	Low	NED	102,0
2749	MZ	TMA, WB	M	90	2	2	0		2	Low	High	NED	42,0
2659	MZ	WB	M	65	2	1	0		3	High	High	DOD	63,7
2799	MZ	TMA	M	53	2	1	0	0	2	High	NA	NED	109,0
2667	MZ	WB	M	55	2	3	0	0	2	High	Low	DOD	101,6
2899	MZ	TMA, WB	M	45	2	3			3	High	High	DOD	24,6
2760	MZ	WB	F	90	2	2	0	0	2	High	High	NED	118,7
2701	MZ	TMA, WB	F	25	2	1			1	High	High	NED	120,0
2703	MZ	TMA	M	140	2	2	0		2	High	NA	DOD	26,0
2855	MZ	WB	F	95	2	2	0	0	3	High	Low	NED	104,0
2674	MZ	TMA	F	70	2	1	0		2	Low	NA	DOD	6,0
2858	MZ	TMA	M	37	2	3		1	2	High	NA	DOD	28,0
2781	MZ	TMA, WB	M	40	2	3			2	Low	Low	NED	114,0
2554	MZ	TMA	M	55	2	2			3	High	NA	NED	108,0
2625	MZ	TMA, WB	M	76	2	2	0		2	High	High	NED	120,0
2663	MZ	TMA	M	50	2	3	1		2	High	NA	DOD	5,0
2752	MZ	TMA	F	50	2	1	0	9	3	Low	NA	NA	NA

DOD, death of disease; M, male; F, female; MT, metastasis; N, node; NA, not available; NED, no evidence of disease; MZ, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; VA, Van Andel Research Institute, Grand Rapids, Michigan; T, tumor stage; TMA, tissue microarray; WB, Western blot.